[The study on the tolerability of perindopril in patients with stable coronary heart disease].
To evaluate the tolerability of perindopril dose-adjustment from 4 mg/d to 8 mg/d in Chinese patients with stable coronary heart disease (CHD). CHD patients with or without hypertension were eligible to this open lebel, multicenter study. Before admission, all patients received and tolerated perindopril 4 mg/d for at least 1 month. Adverse events, blood pressure, heart rate, Na(+), K(+), Cr, BUN at baseline, week 4 and week 8 were recorded. A total of 109 patients with stable CHD were included in this study, 18 out of 109 (16.5%) patients experienced mild adverse events during observation period. No serious adverse event was recorded. Perindopril 8 mg/d was well tolerated in 102 patients (93.6%). One patient (0.9%) withdrew from the study because of severe cough. In patients with elevated baseline blood pressure, switching perindopril from 4 mg/d to 8 mg/d significantly lowered blood pressure from (149.4 +/- 7.6)/(84.1 +/- 11.0) mm Hg (1 mm Hg = 0.133 kPa) to (128.8 +/- 14.2)/(79.5 +/- 8.9) mm Hg (P < 0.01). Serum electrolytes, creatinine and BUN were stable during study period. Perindopril 8 mg/d can be well tolerated by Chinese patients with stable coronary heart disease.